Multicenter prospective nonrandomized controlled clinical trial to prove neurotherapeutic effects of granulocyte colony-stimulating factor for acute spinal cord injury: Analyses of follow-up cases after at least 1 Year

Spine

Volumn 39, Issue 3, 2014, Pages 213-219

  Inada, Taigo ^a   Takahashi, Hiroshi ^a   Yamazaki, Masashi ^a   Okawa, Akihiko ^a   Sakuma, Tsuyoshi ^a   Kato, Kei ^a   Hashimoto, Mitsuhiro ^a   Hayashi, Koichi ^a   Furuya, Takeo ^a   Fujiyoshi, Takayuki ^a   Kawabe, Junko ^a   Mannoji, Chikato ^a   Miyashita, Tomohiro ^a   Kadota, Ryo ^a   Someya, Yukio ^a   Ikeda, Osamu ^a   Hashimoto, Masayuki ^a   Suda, Kota ^b   Kajino, Tomomichi ^b   Ueda, Haruki ^b   Ito, Yasuo ^c   Ueta, Takayoshi ^d   Hanaoka, Hideki ^e   Takahashi, Kazuhisa ^a   Koda, Masao ^a   more..

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hokkaido Spinal Cord Injury Center   (Japan)

^c Kobe Red Cross Hospital   (Japan)

^d SPINAL INJURIES CENTER   (Japan)

^e CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

clinical trial; G CSF; secondary injury; spinal cord injury

Indexed keywords

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SPINAL CORD INJURIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894053275     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0000000000000121     Document Type: Article

References (39)

1. Shibasaki K. National spinal cord injury registry data 2002.1-12. J Jpn Med Soc Spinal Cord Lesion 2005; 18: 271-4.
2. Pannu R, Barbosa E, Singh AK, et al. Attenuation of acute infl ammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res 2005; 79: 340-50. (Pubitemid 40278348)
3. Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second national acute spinal cord injury study. N Engl J Med 1990; 322: 1405-11. (Pubitemid 20152525)
4. Bracken MB, Shepard MF, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the third national acute spinal injury randomized controlled trial. JAMA 1997; 277: 1597-604. (Pubitemid 27231191)
5. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000; 93: 1-7.
6. Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000; 38: 71-6. (Pubitemid 30153991)
7. Polland ME, Apple DF. Factors associated with improved neurologic outcomes in patients with incomplete tetraplegia. Spine 2003; 28: 33-9.
8. Ito Y, Sugimoto Y, Tomioka M, et al. Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury?: a prospective study about neurological recovery and early complications. Spine 2009; 34: 2121-4.
9. Matsumoto T, Tamaki T, Kawakami M, et al. Early complications of high-dose methyl-prednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine 2001; 26: 426-30. (Pubitemid 32184858)
10. Nicola NA, Metcalf D, Matsumoto M, et al. Purifi cation of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identifi cation as granulocyte colony-stimulating factor. J Biol Chem 1983; 258: 9017-23. (Pubitemid 13026729)
11. Roberts AW. G-CSF: a key regulator of neutrophil production, but that's not all ! Growth Factors 2005; 23: 33-41. (Pubitemid 41656869)
12. Gibson CL, Jones NC, Prior MJ, et al. G-CSF suppresses edema formation and reduces interleukin-1 β expression after cerebral ischemia in mice. J Cereb Blood Flow Metab 2005; 25: 431-9.
13. Kawada H, Takizawa S, Takanashi T, et al. Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 2006; 113: 701-10.
14. Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab 2006; 26: 402-13.
15. Schäbitz WR, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 2003; 34: 745-51. (Pubitemid 36307405)
16. Schneider A, Kuhn HG, Schäbitz WR. A role for G-CSF (granulocyte colony-stimulating factor) in the central nervous system. Cell Cycle 2005; 4: 1753-7. (Pubitemid 41827320)
17. Koda M, Nishio Y, Kamada T, et al. Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compressioninduced spinal cord injury in mice. Brain Res 2007; 1149: 223-31. (Pubitemid 46659901)
18. Nishio Y, Koda M, Kamada T, et al. Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol 2007; 66: 724-31. (Pubitemid 47344251)
19. Kawabe J, Koda M, Hashimoto M, et al. Granulocyte colonystimulating factor (G-CSF) exerts neuroprotective effects via promoting angiogenesis after spinal cord injury in rats. J Neurosurg Spine 2011; 15: 414-21.
20. Kadota R, Koda M, Kawabe J, et al. Granulocyte colonystimulating factor (G-CSF) protects oligodendrocyte and promotes hind limb functional recovery after spinal cord injury in rats. PLoS One 2012; 7: e50391.
21. Takahashi H, Yamazaki M, Okawa A, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial. Eur Spine J 2012; 21: 2580-7.
22. Maynard FM, Jr, Bracken MB, Creasey G, et al. International standards for neurological and functional classifi cation of spinal cord injury. American Spinal Injury Association. Spinal Cord 1997; 35: 266-74. (Pubitemid 27235039)
23. Tsutsumi S, Ueta T, Shiba K, et al. Effects of the second national acute spinal cord injury study of high-dose methylprednisolone therapy on acute cervical spinal cord injury-results in spinal injuries center. Spine 2006; 31: 2992-6. (Pubitemid 46005887)
24. Iwasaki H, Kawamoto A, Ishikawa M, et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006; 113: 1311-25. (Pubitemid 43739453)
25. Engelmann MG, Theiss HD, Hennig-Theiss C, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: fi nal results from the G-CSF-STMI (granulocyte colony-stimulating factor STsegment elevation myocardial infarction) trial. J Am Coll Cardiol 2006; 48: 1712-21. (Pubitemid 44528196)
26. Ince H, Petzsch M, Kleine HD, et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: fi nal 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial. Circulation 2005; 112: 173-80.
27. Ripa RS, Jorgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte colony-stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113: 1983-92.
28. Takano H, Hasegawa H, Kuwabara Y, et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 2007; 122: 41-7. (Pubitemid 47503345)
29. Valgimigli M, Rigolin GM, Cittanti C, et al. Use of granulocyte colony-stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profi le. Eur Heart J 2005; 26: 1838-45. (Pubitemid 41253295)
30. Zohlnhofer D, Ott I, Mehilli J, et al. REVIVAL-2 Investigators. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003-10.
31. Shyu WC, Lin SZ, Lee CC, et al. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 2006; 174: 927-33.
32. Nefussy B, Artamonov I, Deutsch V, et al. Recombinant human granulocyte colony-stimulating factor administration for treating amyotrophic lateral sclerosis: a pilot study. Amyotroph Lateral Scler 2010; 11: 187-93.
33. Zhang Y, Wang L, Fu Y, et al. Preliminary investigation of effect of granulocyte colony-stimulating factor on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 430-1.
34. Sakuma T, Yamazaki M, Okawa A, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of compression myelopathy, part 1: a phase I and IIa clinical trial. Eur Spine J 2012; 21: 482-9.
35. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (fi lgrastim) mobilization and blood stem cell apheresis from normal donors and analysis of charge for procedures. Transfusion 1996; 36: 590-5. (Pubitemid 26256425)
36. Bensinger WI, Clift TA, Anasetti C, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Stem Cells 1996; 14: 90-105. (Pubitemid 26041424)
37. Murata M, Harada M, Kato S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065-71.
38. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF) occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-9. (Pubitemid 127531528)
39. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a healthy donor. Lancet 1999; 353: 555. (Pubitemid 29078428)